CD28 and cancer: Collectively, these findings underscore the necessity of CD28 co-stimulation for rescuing CD8+ T cells [38], highlight the critical role of the CD28/B7 pathway in PD-1 therapy for cancer patients, and suggest that increased expression of CD28 on PD-1+ CD8+ T cells may indicate a better response to ICIs.